Functional aspects of the renin–angiotensin–aldosterone system and angiotensin II receptor AT1 blockers in arterial hypertension

International Congress Series

Volumn 1237, Issue C, 2002, Pages 87-98

  Contreras, Freddy ^a   de la Parte, Marı́a Antonia ^a   Cabrera, Julio ^a   Ospino, Nestor ^a   Hernández, Rafael ^b   Hernández, Marı́a J ^b   Lezama, Edwin ^a   Velasco, Manuel ^a  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b UNIVERSIDAD CENTROCCIDENTAL LISANDRO ALVARADO   (Venezuela)

Author keywords

Angiotensin II AT1 receptor blockers; Hypertension; Renin angiotensin system

Indexed keywords

EID: 67649326770     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0531-5131(01)00578-7     Document Type: Article

References (35)

1. Mazzolai, L., Burnier, M., Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf. 21:1 (1999), 23–33.
2. Cohn, J.N., Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in heart failure trial. Cardiology 91:Suppl. 1 (1999), 19–22.
3. Dostal, D.E., et al. Intracardiac detection of angiotensinogen and renin: a localized renin angiotensin system in neonatal rat heart. Am. J. Physiol. 263 (1992), C838–C850.
4. Milsted, A., et al. Atrocity cultures derived from human brain tissue express angiotensinogen mRNA. Proc. Natl. Acad. Sci. U. S. A. 87:15 (1990), 5720–5723.
5. Raizada, M.K., et al. Increased angiotensin II type I receptor gene expression in neuronal cultures from spontaneously hypertensive rats. Endocrinology 132:4 (1993), 1715–1722.
6. Dzau, V.J., Re, R., Tissue angiotensin system in cardiovascular medicine: a paradigm shift?. Circulation 8:1 (1994), 493–498.
7. Hipertensión arterial, urgencia, emergencia hipertensiva e hipertensión maligna. Contreras, F., Blanco, M., (eds.) Fisiopatologı́a, 1997, McGraw-Hill Interamericana de Venezuela, 106–120.
8. Contreras, F., Terán, L., Barreto, N., De la Parte, M., Simonovis, N., y Velasco, M., Aspectos funcionales del sistema renina angiotensina aldosterona y bloqueantes de los receptores AT1 de angiotensina II en hipertensión arterial. Arch. Venez. Farm. Ter. 19 (2000), 121–128.
9. Benter, I.F., Diz, D.I., Ferrario, C.M., Cardiovascular actions of angiotensin-(1–7). Peptides 14 (1993), 674–684.
10. Li, P., Chappell, M.C., Ferrario, C.M., Brosnihan, K.B., Angiotensin-(1–7) augments bradykinin-induced vasodilatation by competing with ACE and releasing nitric oxide. Hypertension 29 (1997), 394–400.
11. Jackson, E., Garrison, J.C., Renin angiotensin. Goodman and Gilman's, the Pharmacological Basis of Therapeutics, 9th edn., 1996, Mc Graw-Hill, 785–811.
12. Gillies, L.K., Werstiuk, E.S., Lee, R.M.K.W., Cross-over study comparing effects of treatment with an angiotensin converting enzyme inhibitor and an angiotensin II type 1 receptor antagonist on cardiovascular changes in hypertension. J. Hypertens. 16 (1998), 477–486.
13. Chung, O., Csikon, T., Unger, T., Angiotensin II receptor pharmacology and AT1 receptor blockers. J. Hum. Hypertens. 13:Suppl. 1 (1999), S11–S20.
14. Goldberg, M.R., Bradstreet, T.E., McWilliams, E.J., et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin–angiotensin–aldosterone system in hypertensive patients. Hypertension 25 (1995), 37–46.
15. Burnier, M., Brunner, H.R., Comparative antihypertensive effects of angiotensin II receptor antagonists. J. Am. Soc. Nephrol. 10:Suppl. 12 (1999), S278–S282.
16. Mimran, A., Ribstein, J., Angiotensin receptor blockers: pharmacology and clinical significance. Am. Soc. Nephrol. 10:Suppl. 12 (1999), S273–S277.
17. Gavras, H., Historical evolution of angiotensin II receptor blockers therapeutic advantages. Post Grad. Med. J. 74:877 (1998), 658–661.
18. Moser, M., Hypertension treatment and the prevention of coronary heart disease in the elderly. Am. Fam. Physician 59:5 (1999), 1248–1256.
19. Adams, M., Trudeau, I., Irbersartan: review of pharmacology and comparative properties. Can. J. Clin. Pharmacol. 7:1 (2000), 22–31.
20. Spence, J., Efficacy of Angiotensin II antagonism in hypertension. Can. J. Cardiol. 15:Suppl. F (1999), 33F–35F.
21. Fogari, R., Mugellini, A., Zoppi, A., Foggari, E., Marasi, G., Pesce, R., Banderali, A., A double-blind, crossover study of the antihypertensive efficacy of Angiotensin II-receptor antagonists and their activation of the renin–angiotensin system. Curr. Ther. Res. 61:10 (2000), 669–679.
22. Velasco, M., Silva, H., Morillo, J., Pellicer, R., Ramı#x0301;rez, A., Urbina, A., et al. Haemodynamic effects of enalapril, a new converting enzyme inhibitor, in hypertensive patients. Eur. J. Clin. Pharmacol. 29 (1985), 17–20.
23. Velasco, M., Urbina, A., Silva, H., Fonseca, R., Guevara, J., et al. A double blind parallel, comparative evaluation of amlodipine vs. captopril in the monotherapeutic treatment of mild and moderate essential hypertension. J. Cardiovasc. Pharmacol. 67 (1991), S32–S34.
24. Preston, R.A., Hirsh, M.J., Oster, J.R., Oster, H.R., Drug-induced hyperkalemia. Am. J. Ther. 5:2 (1998), 125–132.
25. Leenen, F.H., Cardiovascular consequences of sympathetic hyperactivity. Can. J. Cardiol. 15:Suppl. A (1999), 2A–7A.
26. Contreras, F., Rivera, M., Vásquez, J., de la Parte, M.A., Velasco, M., Diabetes and hypertension physiopathology and therapeutics. J. Hum. Hypertens. 14:S1 (2000), 26–31.
27. Contreras, F., Rivera, M., Vásquez, J., de la Parte, M.A., Velasco, M., Endothelial dysfunction in arterial hypertension. J. Hum. Hypertens. 14:S1 (2000), 20–25.
28. Champlain, J., Karas, M., Toal, C., Nadeau, R., Larchelle, P., Effects of antihypertensive therapies on the sympathetic nervous system. Can. J. Cardiol. 15:Suppl. A (1999), 8A–14A.
29. Thurmann, P.A., Angiotensin II Antagonism and the heart: Valsartan in left ventricular hypertrophy. Cardiology 91:Suppl. 1 (1999), 3–7.
30. Nalbantgil, S., Yilmaz, H., Gurun, C., Ozerkan, F., Nalbantgil, I., Onder, R., Effects of Valsartan and enalapril on regression of left ventricular hypertrophy in patients with mild to moderate hypertension: a randomized double-blind study. Curr. Ther. Res. 61:6 (2000), 331–339.
31. Simko, F., Simko, J., Heart failure and angiotensin converting enzyme inhibition: problems and perspectives. J. Physiol. Res. 48:1 (1999), 1–8.
32. Allikmets, K., Parik, T., Viigimaa, M., The renin–angiotensin system in essential hypertension: associations with cardiovascular risk. Blood Pressure 8:2 (1999), 70–78.
33. Willenheimer, R., Dahlos, B., Rydberg, E., Erhardt, L., AT1 receptor blockers in cases of hypertension and heart failure; clinical experience and future tendencies. Eur. Heart J. 20 (1999), 997–1008.
34. Gremmler, B., Kunert, M., Schleiting, H., Ulbricht, L., Improvement of cardiac output in patients with severe heart failure by use of ACE inhibitors combined with the AT1-antagonist Eprosartan. Eur. Heart J. Failure 2:2 (2000), 183–187.
35. Mackenzie, H.S., Ziai, F., Omer, S.A., Nadim, M.K., Taal, M.W., Angiotensin receptor blockers in chronic renal disease: the promise of a bright clinical future. J. Am. Soc. Nephrol. 10:Suppl. 1 (1999), S283–S286.